---
document_datetime: 2026-02-06 10:17:41
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rayvow-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: rayvow-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.560377
conversion_datetime: 2026-02-09 22:22:14.319724
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## RAYVOW

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber      | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|------------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA_IN / | E.4Changeinthenameand/or addressof | 05/02/2026                          |                                          | SmPC,                           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000315499                | the marketing Term name: E.4 authorisation holder, ASMF holder, storage site of the master and/or working cell bank, manufacturing site for an active substance, intermediate or finished product, primary and/or secondary packaging site, manufacturer responsible for batch release, site where quality control takes place, and/or supplier of a packaging component, medical device (part), starting material, reagent and/orexcipient(whenmentioned in the dossier-E.4.a)The change in the name and/or address concerns the marketing authorisationholder-Accepted   |            | Labelling and PL   |
|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------|
| Article 61(3) / EMA/N/0000303870 | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contactdetailsoflocalrepresentativeand deletion of 'United Kingdom (Northem Ireland)' from the list of local representatives in line with the QRD templatev10.4.Additionally,theMAH took theopportunity tointroduceminor editorial amendments.                                                                                                                                                                                                                                     | 21/10/2025 | PL                 |